Searched for
HALOL PLANT USFDA
Sun Pharma gets eight observations from USFDA for Halol plantSun Pharma announced that the USFDA issued a Form 483 with eight observations after inspecting its Halol manufacturing plant in Gujarat. Th...- Can Sun Pharma's quarterly show reinforce investor confidence in stock?The company intends to increase its specialty drug portfolio in its core areas of dermatology and ophthalmology. This comes at a time when ...
- Sun Pharma recalls over 10,000 bottles of generic anti-depression drug in USAs per the USFDA, Sun Pharma is recalling the affected lot due to "presence of foreign substance: Customer complaint for the presence of da...
- USFDA conducting inspection of Mohali plant: Sun PharmaThe inspection by the United States Food and Drug Administration (USFDA) started on September 10, 2018 and is ongoing, Sun Pharma said in a...
- Sun Pharma gets VAI at Halol facility from USFDA; stock surges 8%With the rally, the stock moved above its 50-, 100- and 200-DMAs.
- Sun Pharma tanks 3% on surprise USFDA visit to Dadra plantThe stock fell 2.69% to hit a low of Rs 668 on BSE.
- USFDA subjects SPARC Xelpros nod to 'satisfactory resolution'Earlier this month, Sun Pharma said the US health regulator had made nine observations after the completion of inspection of its Halol faci...
- USFDA report on Halol unit to be positive in long-term: SunThe company's Halol facility recently underwent an inspection by the US Food and Drug Administration (USFDA).
- Sun Pharma EPS may fall by up to 6% on USFDA notice on Halol plantThe US FDA issued the notice on Tuesday with nine inspectional observations after an onsite inspection of Sun Pharma’s Halol facility in Gu...
- US FDA finds fault in accuracy of test methods at Sun’s Halol siteThe agency also found that scientifically sound and appropriate lab control mechanisms were not established.
- USFDA made 9 observations post Halol unit inspection: Sun PharmaThe United States Food and Drug Administration (USFDA) inspected the Halol facility from November 17, 2016 through December 1, 2016, Sun Ph...
- FDA issues observations post Sun Pharma Halol plant inspectionThe approval of several of Sun's key drugs in the United States, the drugmaker's biggest market, depends on the clearance on its Halol plan...
- Sun Pharma shares set to extend losses for fourth day on rising concern over Halol facilityETNow on Tuesday reported that the USFDA has informed that the Halol facility has issued a 14-page Form 483 post inspection.
- For Sun Pharma, a lot rides on USFDA's report on Halol PlantThe Sun Pharma stock has appreciated 13% since the announcement of its second quarter performance on November 10.
- Sun Pharma rises 2% as USFDA issues 7 observations on Mohali sitePrabhudas Lilladher said the current price still does not reflect key positives like Ranbaxy integration benefits, Halol plant resolution a...
- Sun Pharma to ask FDA in Q1 FY17 for Halol re-inspectionDrug major Sun Pharmaceutical Industries may ask the US health regulator in the first quarter of next fiscal for re-inspection of its Halol...
- Expect delay in start of royalty from 2 new drugs: SPARCSun Pharma Advanced Research Company (SPARC) expects further delay in start of royalty income from its two new drug applications, including...
- Leaking ceilings, procedural lapses at Sun Pharma's Halol plant: USFDAThe warning letter follows inspection of the Halol facility in September 2014 by US Food and Drug Administration (USFDA) inspectors.
- Sun Pharma shares a good buy despite short-term painStock may see a sell-off on earnings downgrades & FDA warning, but co has not revised revenue guidance & FIs have steadily raised holdings.
- Focus on getting Ranbaxy's plants USFDA nod one at a time: Sun PharmaSun Pharma, which acquired Ranbaxy in a $4 bn deal, feels it is important for the merged entity to "re-establish" the trust between Ranbaxy...
Load More
